Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 27
---
 the Series L Warrants and the  
 Placement Agent Warrants, after deducting the estimated placement agent fees and estimated 
 offering expenses.                                                                         |

The
amounts shown below are unaudited and the pro forma and pro forma as-adjusted numbers represent management’s estimate. The pro
forma and pro forma as-adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual
public offering price and other terms of this offering determined at pricing. The information in this table should be read in conjunction
with and is qualified by reference to the financial statements and notes thereto and other financial information contained in this prospectus
and incorporated by reference in this prospectus.

| (£ in thousands)          |     | As of June 30, 2025 |        |     |           |     |                   |        |
|:--------------------------|:----|:--------------------|-------:|:----|----------:|:----|:------------------|-------:|
|                           |     | Actual              |        |     | Pro Forma |     | Pro               
 Forma As-Adjusted |        |
| Cash and cash equivalents |     |                     |  4,036 |     |     4,308 |     |                   | 15,883 |
| Long-term debt            |     |                     |     -- |     |        -- |     |                   |     -- |
| Total equity              |     |                     | 11,436 |     |    11,708 |     |                   | 23,283 |
| Total capitalization      |     |                     | 11,436 |     |    11,708 |     |                   | 23,283 |

_____________

| (1) | A                                                                                           
 $1.00 increase or decrease in the assumed combined public offering price of $4.07 per Unit, 
 which is the last reported sale price of our Depositary Shares on the NASDAQ Capital Market 
 on December 9, 2025, would increase or decrease, as appropriate, our pro forma as-adjusted  
 cash and cash equivalents, total equity and total capitalization by approximately £3.08     
 million, assuming the number of units offered by us as set forth on the cover page of       
 this prospectus remains the same, and after deducting the estimated placement agent fees    
 and estimated offering expenses payable by us.                                              |

| (2) | All proceeds from the sale of the units have been reflected within Total equity for